sabcs 2018 - oncoletter€¦ · committee member for the impassion130 and kate2 trials this study...

10
SABCS 2018

Upload: others

Post on 02-Jun-2020

1 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: SABCS 2018 - oncoletter€¦ · committee member for the IMpassion130 and KATE2 trials This study is sponsored by F. Hoffmann-La Roche, Ltd Editorial support, funded by the sponsor,

SABCS 2018

Page 2: SABCS 2018 - oncoletter€¦ · committee member for the IMpassion130 and KATE2 trials This study is sponsored by F. Hoffmann-La Roche, Ltd Editorial support, funded by the sponsor,

SABCS 2018

Page 3: SABCS 2018 - oncoletter€¦ · committee member for the IMpassion130 and KATE2 trials This study is sponsored by F. Hoffmann-La Roche, Ltd Editorial support, funded by the sponsor,

SABCS 2018

Page 4: SABCS 2018 - oncoletter€¦ · committee member for the IMpassion130 and KATE2 trials This study is sponsored by F. Hoffmann-La Roche, Ltd Editorial support, funded by the sponsor,

SABCS 2018

Page 5: SABCS 2018 - oncoletter€¦ · committee member for the IMpassion130 and KATE2 trials This study is sponsored by F. Hoffmann-La Roche, Ltd Editorial support, funded by the sponsor,

SABCS 2018

Page 6: SABCS 2018 - oncoletter€¦ · committee member for the IMpassion130 and KATE2 trials This study is sponsored by F. Hoffmann-La Roche, Ltd Editorial support, funded by the sponsor,

SABCS 2018

Page 7: SABCS 2018 - oncoletter€¦ · committee member for the IMpassion130 and KATE2 trials This study is sponsored by F. Hoffmann-La Roche, Ltd Editorial support, funded by the sponsor,

SABCS 2018

Page 8: SABCS 2018 - oncoletter€¦ · committee member for the IMpassion130 and KATE2 trials This study is sponsored by F. Hoffmann-La Roche, Ltd Editorial support, funded by the sponsor,

SABCS 2018

Page 9: SABCS 2018 - oncoletter€¦ · committee member for the IMpassion130 and KATE2 trials This study is sponsored by F. Hoffmann-La Roche, Ltd Editorial support, funded by the sponsor,

SABCS 2018

Page 10: SABCS 2018 - oncoletter€¦ · committee member for the IMpassion130 and KATE2 trials This study is sponsored by F. Hoffmann-La Roche, Ltd Editorial support, funded by the sponsor,

SABCS 2018